BHST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioHarvest Sciences Inc (BHST) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company shows potential for growth in the long term, the current technical indicators, lack of significant trading signals, and mixed financial performance suggest it is better to wait for clearer entry points or more positive catalysts.
The MACD is positive but contracting, indicating a weakening bullish momentum. RSI is neutral at 47.832, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot point of 4.444, with key support at 4.181 and resistance at 4.708. Overall, the technical indicators do not suggest a strong buy opportunity.
Analyst from Roth Capital initiated coverage with a Buy rating and a $10 price target, citing the company's botanical synthesis platform, rapid growth, and emerging profitability. Gross margin increased to 61.43% in Q3 2025, up 8.15% YoY.
The stock has bearish moving averages, and there are no significant hedge fund or insider trading trends. No recent news or congress trading data is available.
In Q3 2025, revenue increased by 38.66% YoY to $9,067,000, showing strong top-line growth. However, net income and EPS declined, indicating ongoing profitability challenges. The gross margin improved to 61.43%, reflecting operational efficiency gains.
Roth Capital analyst Sean McGowan initiated coverage with a Buy rating and a $10 price target, citing rapid growth, an expanding footprint, and emerging profitability. The company is expected to turn sustainably cash flow positive by 2027.
